Predict your next investment

HEALTHCARE | Drug Development
talontx.com

See what CB Insights has to offer

Stage

Acq - P2P | Acquired

Valuation

$0000 

About Talon Therapeutics

Talon Therapeutics is a biopharmaceutical company that develops and commercializes new and differentiated cancer therapies. Its lead product includes Marqibo, which is a novel sphingomyelin/cholesterol liposome encapsulated formulation of vincristine for acute lymphoblastic leukemia and non-Hodgkin's lymphoma. The company's product candidates comprise Menadione topical lotion, a novel cancer supportive care product candidate, which is in a Phase II trial for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors in the treatment of cancers.

Talon Therapeutics Headquarter Location

400 Oyster Point Boulevard Suite 200

South San Francisco, California, 94080,

United States

650-588-6404

Latest Talon Therapeutics News

Acute Lymphocytic/Lymphoblastic Leukemia Drugs Market Earnings Margins, Value Of Production & Consumption Demand Figures 2019-2025

Feb 4, 2020

Acute Lymphocytic/Lymphoblastic Leukemia Drugs Market (6 Forces Forecast 2019-2025) research report offers in-intensity insight of the Acute Lymphocytic/Lymphoblastic Leukemia Drugs industry masking all vital parameters along with Marketing Channel, Direct Marketing, Indirect Marketing, Brand Strategy, Pricing Strategy, Market Positioning, Target Client, and Distributors/Traders List. Acute Lymphocytic/Lymphoblastic Leukemia Drugs Market report includes an extensive analysis of competition by topmost prime manufacturers (Erytech Pharma, Spectrum Pharmaceuticals, Pfizer, Sigma-Tau, Shire, Genzyme Corporatio, GSK, Amgen, EUSA Pharma, ARIAD Pharmaceuticals, Talon Therapeutics, Enzon, Inc., Nova Laboratories, Bristol-Myers Squibb, Silvergate Pharmaceuticals) which providing information such as Company Profiles, Product Revenue, Market Size, Trade, Sales Volume, and Industry Share by Type, Specifications and Contact Information. The Acute Lymphocytic/Lymphoblastic Leukemia Drugs market report also reviews industry segments and sub-segments, along with production technology, types of product, application and market verticals. Get Free Sample PDF (including full TOC, Tables and Figures) of Acute Lymphocytic/Lymphoblastic Leukemia Drugs [email protected]   https://www.researchmoz.us/enquiry.php?type=S&repid=1934087    Acute Lymphocytic/Lymphoblastic Leukemia Drugs Market Target Audience Production Companies, Suppliers, Channel Partners, Marketing Authorities, Subject Matter Experts, Research Institutions, Financial Institutions, Market Consultants, Government Authorities. Scope of Acute Lymphocytic/Lymphoblastic Leukemia Drugs Market: Acute lymphoblastic leukemia(ALL) is acancerof thelymphoid lineofblood cellscharacterized by the development of large numbers ofimmature lymphocytes. In 2017, the global market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the market based on company, product type, application and key regions. On the basis of product, this report displays the sales volume, revenue (Million USD), product price, Acute Lymphocytic/Lymphoblastic Leukemia Drugs market share and growth rate of each type, primarily split into- Chemotherapy Stem cell Transplantation On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, Acute Lymphocytic/Lymphoblastic Leukemia Drugs market share and growth rate of Acute Lymphocytic/Lymphoblastic Leukemia Drugs for each application, including- Hospital Pharmacy Geographically, the report includes the research on production, consumption, revenue, Acute Lymphocytic/Lymphoblastic Leukemia Drugs market share and growth rate, and forecast (2019-2025) of the following regions: United States, China, Japan, India, Other Regions Europe (Germany, UK, France, Italy, Spain, Russia, Poland) Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam) Central and South America (Brazil, Mexico, Colombia) Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria) Key Questions Answered in the Report: How is the Acute Lymphocytic/Lymphoblastic Leukemia Drugs market expected to Grow In Terms Of Value during the study period? What are the Competition Developments and Trends in the Acute Lymphocytic/Lymphoblastic Leukemia Drugs market? What are the underlying Macro-Economic and Industry Factors impacting the growth of the Acute Lymphocytic/Lymphoblastic Leukemia Drugs market? What are the Key Challenges, Opportunities, and Improvements faced by market players in the global Acute Lymphocytic/Lymphoblastic Leukemia Drugs market? Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Talon Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Talon Therapeutics is included in 2 Expert Collections, including Nanobiotechnology.

N

Nanobiotechnology

704 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.